首页> 外文学位 >Effects of drug-carrier interactions on drug dissolution from binary and ternary matrices.
【24h】

Effects of drug-carrier interactions on drug dissolution from binary and ternary matrices.

机译:药物-载体相互作用对药物从二元和三元基质中溶出的影响。

获取原文
获取原文并翻译 | 示例

摘要

For nearly five decades, pharmaceutical researchers have studied solid solutions of drugs in polymers as a potential means to enhance the dissolution of drugs with poor aqueous solubility. This has become of greater importance in recent years because most new potential drug compounds (new chemical entities) exhibit poor water solubility and present great challenges to scientists who must design dosage forms from which the drugs are bioavailable.;During the formulation of a solid solution, the drug undergoes physical but not chemical alterations that increase its chemical potential in the formulation relative to that of the pure drug in its stable form. This increased chemical potential is responsible for enhanced dissolution as well as physical instabilities, such as amorphous to crystalline conversions and precipitation within the solid state. The chemical potential is derived from the Gibbs free energy, so it is reasonable to explain the behavior of solid solution systems in terms of thermodynamics. Solid solutions and dispersions have been extensively studied by pharmaceutical scientists, both with regard to manufacturing aspects and the proposal of various models in attempts to explain the physical bases for how these systems work.;Recently, Dave and Bellantone proposed a model based on the thermodynamic changes resulting from the formulation of binary solid solutions of a drug in the polymer PVP. Their model introduced a modification of the F-H theory, which was used to quantify the drug-polymer interaction energies and calculate the entropy of mixing of the drug and polymer.;In this work, the model of Dave and Bellantone was extended to include three-component systems, consisting of one drug mixed in a carrier matrix consisting of mixture of two polymers or a polymer and a surfactant. For this research, solid solutions were formed using various drug weight fractions in the formulations. The study focused on the following points: (1) Prepare solid solution formulations and perform appropriate physical characterizations. (2) Characterize the increase in drug dissolution rates resulting from solid solution formulations. (3) Relate the initial dissolution rates to the drug solubility. (4) Explain the solubility enhancement from solid solution dosage in terms of the drug polymer interactions using the extended thermodynamic model.;Two poorly water soluble drugs, levonorgestrel (LEVO) and ethinyl estradiol (EE) were formulated in seven solid solution preparations comprised of four carrier systems. Materials used as carriers included various combinations of the polymers PVP K-30, Copovidone (COP), Poloxamer 182, and the surfactant TweenRTM 20. Additionally, ibuprofen (IBU) was used in three formulations consisting of various combinations of PVP K-30, Copovidone and TweenRTM 20. Formulations with various drug weight fractions (0.5%--30%) were prepared using the solvent evaporation technique. Each formulation was tested for dissolution using intrinsic dissolution apparatus (USP). The solid solutions were compressed into tablets into the sample die that maintained a constant surface area during the dissolution process.;DSC, XRD and NIRS scans identified that the crystalline peaks of the drug disappeared with the addition of the polymer for all ratios of EE, indicating the formation of solid solutions (to within the limits of detection of the equipment). This was also observed for the LEVO dispersions up to 10% drug loading. At higher drug loading, solutions were formed but some small degree crystallinity was also present.;For each experiment, the initial dissolution rates were obtained from the slope of the mass dissolved vs. time plots taken at early times, and volume normalized initial dissolution rates RV were calculated by dividing the initial dissolution rate by the volume fraction of the drug in the formulation. Comparison of the RV values for the various formulations with a reference RV (typically that of the pure drug or of the formulation with the highest polymer content) allowed calculation of relative volume normalized dissolution rates (RNV). The various RNV were used in the thermodynamic model for data analyses and to determine the interactions between the drug and carrier molecules. It was generally seen that RNV increased with decreased drug fraction, and was adequately modeled by the equations derived from the extended thermodynamic model.;It was concluded that the model proposed for the binary and ternary systems successfully represented the mechanism of drug-polymer interaction and the energy changes taken place within the dispersion systems. The dissolution data analysis and subsequent understanding of physical modifications in the dispersion systems characterized by XRD, NIRS and DSC further substantiated the findings. The understanding of the fundamental physical might help scientists to predict the effects of mixing various drugs and polymers, and the effects of varying ratios.
机译:近五年来,药物研究人员一直研究药物在聚合物中的固溶体,作为增强水溶性差的药物溶解的潜在手段。近年来,这已变得越来越重要,因为大多数新的潜在药物化合物(新的化学实体)显示出较差的水溶性,并且对必须设计可生物利用这些药物的剂型的科学家提出了巨大的挑战。 ,该药物会发生物理改变,但不会发生化学改变,相对于其稳定形式的纯药物而言,会增加其在制剂中的化学势。这种增加的化学势导致溶解度增加以及物理不稳定性,例如非晶态到晶体的转化以及固态内的沉淀。化学势源自吉布斯自由能,因此从热力学角度解释固溶体系统的行为是合理的。药物科学家已经对固溶体和分散体进行了广泛的研究,涉及制造方面和各种模型的建议,试图解释这些系统如何工作的物理基础。最近,Dave和Bellantone提出了基于热力学的模型。由聚合物PVP中药物的二元固溶体的配制引起的变化。他们的模型引入了FH理论的改进,该模型用于量化药物与聚合物之间的相互作用能并计算药物与聚合物的混合熵。在这项工作中,Dave和Bellantone的模型扩展为包括三个组分系统,由一种药物混合在由两种聚合物或一种聚合物和一种表面活性剂的混合物组成的载体基质中。对于这项研究,在制剂中使用各种药物重量分数形成固溶体。该研究集中在以下几点:(1)制备固溶体配方并进行适当的物理表征。 (2)表征由固溶体制剂引起的药物溶解速率的增加。 (3)将初始溶出度与药物溶解度联系起来。 (4)使用扩展的热力学模型,从固溶体剂量解释药物聚合物之间的溶解度增加;在7种固溶体制剂中配制了两种水溶性差的药物左炔诺孕酮(LEVO)和乙炔雌二醇(EE)。四个载体系统。用作载体的材料包括聚合物PVP K-30,共聚维酮(COP),泊洛沙姆182和表面活性剂TweenRTM 20的各种组合。此外,布洛芬(IBU)用于三种配方,由PVP K-30的各种组合组成, Copovidone和TweenRTM 20使用溶剂蒸发技术制备了具有各种药物重量分数(0.5%-30%)的制剂。使用固有溶出度仪(USP)测试每种制剂的溶出度。将固溶体压缩成片剂,放入样品冲模中,在溶解过程中保持恒定的表面积。DSC,XRD和NIRS扫描发现,对于所有比例的EE,通过添加聚合物,药物的结晶峰均消失了,指示形成固溶体(在设备检测范围内)。对于高达10%载药量的LEVO分散液也观察到了这一点。在较高的载药量下,会形成溶液,但也会出现一些小程度的结晶。;对于每个实验,从溶出的质量与早期时间图的斜率中获得初始溶出率,并将体积归一化的初始溶出率通过将初始溶出率除以制剂中药物的体积分数来计算RV。通过将各种制剂的RV值与参考RV(通常是纯药物或具有最高聚合物含量的制剂)的RV值进行比较,可以计算相对体积归一化溶出速率(RNV)。热力学模型中使用了各种RNV进行数据分析并确定药物与载体分子之间的相互作用。普遍认为RNV随药物分数的降低而增加,并且可以通过扩展热力学模型导出的方程进行充分建模。;结论是,针对二元和三元系统提出的模型成功地代表了药物-聚合物相互作用的机理以及能量在分散系统中发生的变化。溶出数据分析和对XRD,NIRS和DSC表征的分散体系中物理修饰的后续理解进一步证实了这一发现。对基本物理原理的理解可能有助于科学家预测各种药物和聚合物混合的效果以及不同比例的效果。

著录项

  • 作者

    Iqbal, Zafar.;

  • 作者单位

    Long Island University, The Brooklyn Center.;

  • 授予单位 Long Island University, The Brooklyn Center.;
  • 学科 Pharmaceutical sciences.;Physical chemistry.;Materials science.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 188 p.
  • 总页数 188
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号